Latest MIMS bulletin complements monthly product update

MIMS Spotlight is the latest email bulletin from MIMS, designed specifically to complement MIMS Product Update. Each issue draws together the latest MIMS news and prescribing resources for a key therapeutic area.

You can sign up for MIMS Spotlight at www.healthcarerepublic.com/bulletins.

Coinciding with the global year against musculoskeletal pain, the next issue of MIMS Spotlight will highlight major recent drug launches in the musculoskeletal field, including the first therapeutic antibody for osteoporosis and the first new gout treatment for 40 years. Alongside, it will offer a selection of our helpful prescribing resources, including patient fact sheets and drug comparison tables.

MIMS Spotlight is designed to help you:

  • choose the right treatments
  • follow national guidelines
  • support and advise your patients
  • keep abreast of emerging medicines.

Topics covered in previous issues of MIMS Spotlight include diabetes, women’s health and digestive disorders. Future issues will collate prescribing news and resources relevant to cardiovascular conditions, respiratory disease and other conditions commonly encountered in primary care.

Make sure you’re getting the most out of MIMS. Visit www.healthcarerepublic.com/bulletins to register for MIMS Spotlight.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

A healthcare professional holds a syringe in one hand while pinching a baby's thigh as they prepare to administer a vaccination.

Changes to routine vaccination schedule recommended by JCVI

The Joint Committee on Vaccination and Immunisation...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...